ClinicalTrials.gg
CompletedNCT00739466BLASTUpdated Jan 20, 2016

Biorest Liposomal Alendronate With Stenting sTudy (BLAST)

A Phase 2 interventional study of Liposomal Alendronate and Liposomal Alendronate in Coronary Artery Stenosis, sponsored by BIOrest Ltd.. Completed at 12 sites in Israel. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-01-20.

Sponsored by BIOrest Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Coronary Stenosis with a site in Israel — none open to participants now, 2 under way, 1 of them phase 3. Coronary Stenosis · Israel.

Enrollment
9th of 11
226 · median 812
Started
2008
the only one that year
Phase 2
2 of 15
none open now
Registered
4th of 15
by date
Lead sponsor
1 of 15
BIOrest Ltd.

Among the 15 studies in Coronary Stenosis with a site in Israel, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is one of 2 in phase 2, and was the 4th registered.

Coronary Stenosis

326 studies on the registry are indexed under Coronary Stenosis; 57 are open to participants now.

Browse Coronary Stenosis studies →

Open to participants now

None of the 15 studies in Coronary Stenosis with a site in Israel is open now. The open studies under Coronary Stenosis, anywhere →

Who these studies take

Of the 40 Coronary Stenosis studies recruiting now, 33 (83%) set no upper age limit and 3 (8%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Coronary Stenosis with a site in Israel as a file.
02

Study summary

The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare metal stent.

Study hypothesis: Liposomal Alendronate will reduce in-stent restenosis as compared to placebo.

Read the detailed description

This is a Phase II dose-finding, randomized, multi-center, prospective, double blind clinical study. Subjects undergoing percutaneous coronary intervention (PCI) with the Presillion™ CoCr bare metal stent will be randomized into three groups and administered (in a single dose intravenously (IV) through a peripheral venous catheter) either: low dose Liposomal Alendronate of 0.001 mg, high dose Liposomal Alendronate of 0.01 mg, or placebo (IV saline infusion) on a 1:1:1 basis.

All subjects will undergo angiographic follow-up at 6 months and 110 subjects enrolled from pre-specified sites will undergo intravascular ultrasound (IVUS) at baseline and follow-up at 6 months.

03

Conditions studied

  • Coronary Artery Stenosis

Browse trials for

Keywords

  • Liposomal Alendronate
  • Percutaneous coronary intervention
  • Coronary stenting
  • de novo stenotic lesions
  • Native coronary arteries
  • Restenosis
  • Bare metal stent
  • Presillion CoCr coronary stent
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is eligible for percutaneous coronary intervention .
  2. Subject is an acceptable candidate for coronary artery bypass graft surgery.
  3. Subject has stable angina pectoris
  4. Subject is a candidate for elective stenting of up to 2 lesions.

Exclusion criteria

Exclusion Criteria:

General

  1. Any planned elective surgery or percutaneous intervention within 6 months post-procedure.
  2. A previous coronary interventional procedure of any kind within 30 days prior to the procedure.
  3. Subject requires a staged procedure of either the target or any non-target vessel within 9 months post-procedure.
  4. Any drug eluting stent (DES) deployment within the past 12 months.
  5. Any planned drug eluting stent (DES) deployment during the procedure associated with this study or within 3 months following the index procedure.
  6. Known or to aspirin or clopidogrel or a sensitivity to contrast media, which cannot be adequately pre-medicated
  7. Concurrent medical condition with a of less than 12 months.
  8. Documented (LVEF) \< 25% at the most recent evaluation.
  9. Evidence of ST elevated myocardial infarction (STEMI) or non-STEMI with troponin (cTn) levels greater than or equal to 3 times the normal limit at any time within 72 hours of the intended trial procedure.
  10. History of cerebrovascular accident or in the last 6 months.
  11. Leukopenia .
  12. Neutropenia
  13. Thrombocytopenia
  14. Serum creatinine level >2.5 mg/dl within 7 days prior to index procedure.
  15. History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.
  16. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel and ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy, Alendronate or sensitivity to contrast media, which cannot be adequately pre-medicated.
  17. History of severe:Gastrointestinal disease,Immunodeficiency,Bone diseases

Angiographic Exclusion Criteria

  1. Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the LAD or Circumflex artery or a branch thereof).
  2. Any previous stent placement within 15 mm (proximal or distal) of the target lesion(s).
  3. Target vessel exhibiting lesions with greater than 60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion(s) based on visual estimate or on-line QCA.
  4. Target lesion(s) exhibiting an intraluminal thrombus (occupying >50% of the true lumen diameter) at any time.
  5. Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX).
  6. The target lesion(s) requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
  7. Target lesion(s) with side branches > 2.0mm in diameter.
  8. Target lesion(s) involving a bifurcation (either stenosis of both main vessel and major branch or stenosis of just major branch).
  9. Target lesion(s) with severe calcification.
  10. Target vessel exhibiting excessive tortuosity that may impede stent delivery and deployment at target lesion(s).
  11. Target lesion(s) located in a native vessel distal to an anastomosis with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    low dose

    Liposomal Alendronate dose of 0.001 mg

    Drug: Liposomal Alendronate

  • Experimental
    high dose

    Liposomal Alendronate dose of 0.01 mg

    Drug: Liposomal Alendronate

  • Placebo comparator
    placebo

    IV saline infusion

    Drug: Saline infusion (placebo)

Interventions

  • IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours

    Also known as: LA

  • IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours

    Also known as: LA

  • DrugSaline infusion (placebo)

    IV saline infusion during the index procedure (coronary stent implantation) over 2 hours

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. In-stent late loss: measured at 6 months post-procedure as determined by quantitative coronary angiography (QCA).

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Major Adverse Cardiac Events (MACE)

    Time frame: at 30, 180 and 360 days as well as yearly through 5 years post-procedure

07

Study locations

12 sites
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Bnei Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Health Care Campus
    Haifa, 31096, Israel
  • Lady Davis Carmel Medical Center
    Haifa, 34362, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Meir Medical Center
    Kfar Saba, 44281, Israel
  • Western Galilee Hospital, Nahariya
    Nahariya, 22100, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • The Baruch Padeh Medical Center, Poriya
    Poriya, 15218, Israel
  • Sheba Medical Center, Tel Hashomer
    Ramat Gan, 52521, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • The Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
08

References and documents

Publications

  • Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. Am Heart J. 2013 Feb;165(2):234-40.e1. doi: 10.1016/j.ahj.2012.10.023. Epub 2012 Dec 11. PubMed 23351827 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2008
First posted
Aug 21, 2008
Start
Sep 2008
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Last update
Jan 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00739466
Lead sponsor
BIOrest Ltd.
Collaborators
Baim Institute for Clinical Research, Cardiovascular Research Foundation, New York, Stanford University
Responsible party
Sponsor
First posted
Aug 21, 2008
Start date
Sep 2008
Primary completion
Dec 2015
Completion
Dec 2015
Last update
Jan 20, 2016

Study contacts

Prof Shmuel Banai, MD
principal investigator · The Tel Aviv Sourasky Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion